Cargando…
Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
OBJECTIVE: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict resp...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medical Research and Education Association
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089141/ https://www.ncbi.nlm.nih.gov/pubmed/35110134 http://dx.doi.org/10.5152/eurjrheum.2021.20202 |